Investor Relations

Oragenics Extends Collaboration with the National Research Council of Canada to Develop Vaccine against the Omicron Variant

Read Press Release

Latest Financial Results

Q3 2021

Quarterly Results

Ended Sep 30, 2021

Stock Information

Symbol NYSE American: OGEN
Price Loading...
Change Loading...
Day Range Loading...
52 Wk Range Loading...

Company Overview

Oragenics, Inc. is a development-stage company dedicated to fighting infectious diseases including coronaviruses and multidrug-resistant organisms. Its lead product is Terra CoV-2, an intranasal vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus. The Terra CoV-2 program leverages coronavirus spike protein research licensed from the NIH and the NRC with a focus on reducing viral transmission and offering a more patient-friendly intranasal administration. Its lantibiotics program features a novel class of antibiotics against bacteria that have developed resistance to commercial antibiotics.

Contact Information

Investor Relations
LHA Investor Relations
Kim Golodetz
Senior Vice President, Principal
T: 212-838-3777
kgolodetz@lhai.com

Transfer Agent
Continental Stock Transfer and Trust Company
17 Battery Place
New York, NY 10004
T: 212-509-4000